title: Tumor necrosis factor antagonist-associated neutropenia: comment on the article by Hastings et al.
authors.forename: Spyros
authors.initials: S
authors.lastname: Aslanidis
authors.forename: Athina
authors.initials: A
authors.lastname: Pyrpasopoulou
authors.forename: Areti
authors.initials: A
authors.lastname: Triantafyllou
authors.forename: Panagiota
authors.initials: P
authors.lastname: Anyfanti
authors.forename: Chrysanthos
authors.initials: C
authors.lastname: Zamboulis
authors.forename: Stella
authors.initials: S
authors.lastname: Douma
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000069285:Infliximab; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced*; D011379:Prognosis; D012213:Rheumatic Fever / Q000188:drug therapy; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000097:blood; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab